YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Yarrow Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$19.98+1.67 (+9.12%)
Close on Oct 19, 2026
- Market cap
- $17.14M
- P/E (TTM)
- –
- Dividend yield
- –
Yarrow Bioscience, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q2 25 | Q1 25 | Q2 24 | Q1 24 | Q1 23 | Q4 22 | Q3 22 | Q1 22 | Q4 21 | Q3 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty revenues | – | – | – | – | – | – | $100.00K | $6.00K | $167.00K | $200.00K | $273.00K | $133.00K | – | – |
| Product sales, net | – | – | – | – | – | – | – | – | – | – | $2.02M | $3.95M | – | – |
| License revenues | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Yarrow Bioscience's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.